SmithKline Beecham affirms commitment to clinical laboratories
This article was originally published in Clinica
Executive Summary
Despite the poor performance of SmithKline Beecham's clinical laboratories business in 1995, chief executive Jan Leschly says it is still a "very important asset". In an otherwise good year for the UK/US company, SB Clinical Laboratories recorded a sales increase of just 1% while trading profit dropped 21%.